

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/046,651	SMITH ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Patrick J. Nolan	1644	

**All Participants:**

(1) Patrick J. Nolan.

(2) Astrid Spain.

**Status of Application:** Rejected

(3) \_\_\_\_\_.

(4) \_\_\_\_\_.

**Date of Interview:** 1 April 2005

**Time:** \_\_\_\_\_

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No  
 If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

*The 35 USC 112 2<sup>nd</sup> paragraph over claim 23 was discussed*

Claims discussed:

*20 and 23*

Prior art documents discussed:

**Part II.**

**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

*See Continuation Sheet*

**Part III.**

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

\_\_\_\_\_  
(Examiner/SPE Signature)

\_\_\_\_\_  
(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Applicant agreed that claims 1-19 were cancelled in a preliminary filed 10-19-01, and so they are not pending. Applicant also agreed to an Examiner's amendment removing urine from claim 23 since antibodies are too large to be found in urine and to amend claim 23 by the insertion of and after acites to recite a proper Markush Group. Applicant also agreed to amend claim 20, line 8 by the insertion of comparing the patient IL-16 or RANTES levels to normal controls..